MedTrace Logo

Confirm the Safety and Performance of Avance Solo NPWT System

NCT04754048 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2023-02-24

No results posted yet for this study

Summary

The primary objective of this post market clinical follow-up (PMCF) investigation is to confirm safety and performance of Avance® Solo NPWT System in low to moderate exuding acute (traumatic wounds and flaps and grafts), as well as subacute (e.g., dehisced wounds) wounds when used in accordance with the Instructions for Use, for up to 28 days.

Conditions

  • Acute Wound
  • Traumatic Wound
  • Skin Graft
  • Skin Flap
  • Subacute Wound
  • Dehiscence

Interventions

DEVICE

Avance Solo NPWT System

Wound treatment with Avance Solo NPWT System for up to 28 days.

Sponsors & Collaborators

  • Syntactx

    collaborator NETWORK

  • Molnlycke Health Care AB

    lead INDUSTRY

Principal Investigators

  • Hilde Beele, Prof. Dr. · University Hospital, Ghent

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2022-12-06
Completion
2022-12-06

Countries

  • Belgium
  • France
  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04754048 on ClinicalTrials.gov